Literature DB >> 18228181

Newcastle disease virus as a vaccine vector for humans.

Alexander Bukreyev1, Peter L Collins.   

Abstract

Emerging and re-emerging infectious diseases pose a threat to individuals worldwide and necessitate the development of new vaccines and vaccine platforms. Newcastle disease virus (NDV) is an enveloped cytoplasmic RNA virus of avian origin that is highly attenuated in humans and other primates because of a strong host-range restriction. NDV infects the respiratory tract of non-human primates and appears to remain restricted to that site. As a vaccine vector, NDV induced substantial local and systemic responses against a protein expressed by a foreign gene insert and was protective against pathogen challenge. NDV is antigenically distinct from common human viruses, accommodates foreign sequences with a good degree of stability, can be readily produced in a cell line acceptable for human product development, and exhibits a low incidence of recombination. Because of its natural tropism for the respiratory tract, NDV may be particularly effective for the development of vectored vaccines against respiratory infections as well as infections that can be transmitted through the respiratory tract.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18228181

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  42 in total

1.  Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats.

Authors:  Jinying Ge; Xijun Wang; Lihong Tao; Zhiyuan Wen; Na Feng; Songtao Yang; Xianzhu Xia; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

3.  What are the risks--hypothetical and observed--of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses?

Authors:  Peter L Collins; Alexander Bukreyev; Brian R Murphy
Journal:  J Virol       Date:  2008-10       Impact factor: 5.103

4.  Recombinant Newcastle disease virus expressing H9 HA protects chickens against heterologous avian influenza H9N2 virus challenge.

Authors:  Abdou Nagy; Jinhwa Lee; Ignacio Mena; Jamie Henningson; Yuhao Li; Jingjiao Ma; Michael Duff; Yonghai Li; Yuekun Lang; Jianmei Yang; Fatma Abdallah; Juergen Richt; Ahmed Ali; Adolfo García-Sastre; Wenjun Ma
Journal:  Vaccine       Date:  2016-04-18       Impact factor: 3.641

5.  Site-specific glycosylation of the Newcastle disease virus haemagglutinin-neuraminidase.

Authors:  Cassandra L Pegg; Christine Hoogland; Jeffrey J Gorman
Journal:  Glycoconj J       Date:  2016-12-07       Impact factor: 2.916

6.  Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice.

Authors:  Shin-Hee Kim; Shun Chen; Xi Jiang; Kim Y Green; Siba K Samal
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

7.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

8.  Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.

Authors:  Joshua M DiNapoli; Baibaswata Nayak; Lijuan Yang; Brad W Finneyfrock; Anthony Cook; Hanne Andersen; Fernando Torres-Velez; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

Review 9.  Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.

Authors:  Aseem Pandey; Neetu Singh; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Hum Vaccin       Date:  2010-02-24

10.  Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.

Authors:  Joshua M DiNapoli; Jerrold M Ward; Lily Cheng; Lijuan Yang; Subbiah Elankumaran; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  Vaccine       Date:  2009-01-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.